Influence of factor IX on overall plasma coagulability and fibrinolytic potential as measured by global assay: Monitoring in haemophilia B

Haemophilia

Volumn 14, Issue 1, 2008, Pages 68-77

  Goldenberg, N A ^a,b,c   Bombardier, C ^c   Hathaway, W E ^a,c   Mcfarland, K ^a,c   Jacobson, L ^a,c   Manco johnson, M J ^a,c  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Mountain States Regional Hemophilia and Thrombosis Center   (United States)

Author keywords

Coagulation; Dysfunction; Factor IX; Fibrinolysis; Global assay; Haemophilia

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; AGED; AMPLITUDE MODULATION; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DRUG INFUSION; EUGLOBULIN LYSIS TEST; EX VIVO STUDY; FIBRINOLYSIS; HEMOPHILIA B; HUMAN; HYPOCOAGULABILITY; IN VITRO STUDY; INFANT; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOCYTE POOR PLASMA; WAVEFORM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FACTOR IX; FIBRINOLYSIS; HEMOPHILIA B; HUMANS; INFANT; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 37749019053     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01565.x     Document Type: Article

References (25)

1. Soucie JM, Evatt B, Jackson D, and the Hemophilia Surveillance System Project Investigators. Occurrence of hemophilia in the United States. Am J Hematol 1998; 59: 288-94.
2. Biggs R, Douglas AS, Macfarlane RG et al. Christmas disease: A condition previously mistaken for haemophilia. Br Med J 1952; 2: 1378-82.
3. Green PM. "Hemophilia B-molecular basis". In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia. Oxford, UK: Blackwell Publishing Ltd, 2005: 91-6.
4. Björkman S, Shapiro AD, Bentorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: Implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9.
5. White GC, Rosendaal F, Aledort LM et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
6. Goldenberg NA, Hathaway WE, Jacobson L, McFarland K, Manco-Johnson MJ. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilia plasma as measured by global assay: Monitoring in haemophilia A. Haemophilia 2006; 12: 605-14.
7. Goldenberg NA, Hathaway WE, Jacobson L, Manco-Johnson MJ. A new global assay of coagulation and fibrinolysis. Thromb Res 2005; 116: 345-56.
8. Lefkowitz JB, Nuss R, Haver T et al. Factor IX Denver, ASN 346 → ASP mutation resulting in a dysfunctional protein with defective factor VIIIa interaction. Thromb Haemost 2001; 86: 862-70.
9. Smith AA, Jacobson LJ, Miller BI, Hathaway WE, Manco-Johnson MJ. A new euglobulin clot lysis assay for global fibrinolysis. Thromb Res 2003; 112: 329-37.
10. Antovic A, Blomback M, Sten-Linder S et al. Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma. Blood Coagul Fibrinolysis 2006; 16: 585-96.
11. Dargaud Y, Béguin S, Lienhart A et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
12. Ingerselv J, Poulsen LH, Sorensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in hemophilia. Haemophilia 2003; 9: 348-52.
13. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements -an on monitoring haemostatic response using thrombelastography. Haemophilia 2005; 11 (Suppl. 1): 1-6.
14. Mischke R. Sensitivity of the reaction time of the resonance thrombogram for factor VIII:C and factor IX deficiencies in the blood of dogs with haemophilia A or B. Haemophilia 2000; 6: 575-80.
15. Owren PA. Thrombotest: A new method for controlling anticoagulant therapy. Lancet 1959; 2: 754-8.
16. Bicocchi MP, Pasino M, Rosano C et al. Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B. Haemophilia 2006; 12: 263-70.
17. Noyes CM, Griffith MJ, Roberts HR, Lundblad RL. Identification of the molecular defect in factor IX Chapel Hill: Substitution of histidine for arginine at position 145. Proc Natl Acad Sci USA 1983; 80: 4200-2.
18. Monroe DM, McCord DM, Huang MN et al. Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo. Blood 1989; 73: 1540-4.
19. Ware J, Diuguid DL, Liebman HA et al. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties. J Biol Chem 1989; 264: 11401-6.
20. Miyata T, Sakai T, Siguimoto M et al. Factor IX Amagasaki: A new mutation in the catalytic domain resulting in the loss of both coagulant and esterase activitites. Biochemistry 1991; 30: 11286-91.
21. Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JC, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86: 1035-9.
22. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
23. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
24. Flanders MM, Crist RA, Roberts WL, Rodgers GM. Pediatric reference intervals for seven common coagulation assays. Clin Chem 2005; 51: 1738-42.
25. Allen GA, Wolberg AS, Oliver JA et al. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004; 2: 402-13.